synthesised a series of imidazotetrazine derivatives which exhibited broad-spectrum antitumour activity against murine tumours. The lead compound in this series, mitozolomide, has been extensively studied and is considered to exert its effect by crosslinking DNA (Gibson et al., 1984 and .
Mitozolomide is a pro-drug of the cytotoxic triazene MCTIC (Stevens et al., 1984) . The major site of alkylation by MCTIC is thought to be the O6-position of guanine with additional alkylation also occurring at the N7 position (Hartley et al., 1986) .
Structurally temozolomide lacks the chloroethyl side chain present in mitozolomide and has been developed as a potential alternative to dacarbazine (Stevens et al., 1987) . Bull and Tisdale (1987) showed that there were differences in the ability of mitozolomide and temozolomide to alkylate DNA. At physiological pH temozolomide undergoes chemical degradation to MTIC without the requirement of metabolic activation as in the case of dacarbazine (Figure 1 ) (Stevens et al., 1987; Tsang et al., 1991) .
The Phase I trial of mitozolomide was completed in 1985 (Newlands et al., 1985) and a number of phase II studies were performed which showed minor antitumour activity in small cell carcinoma of the lung and in malignant melanoma, but severe and unpredictable myelosuppression precluded its further clinical development (Heriat et al., 1988; Blackledge et al., 1989; Harding et al., 1988; Neijt et al., 1987; van Oosterom et al., 1989; Gundersen et al., 1987; Schornagel et al., 1986) . Temozolomide was selected for further clinical development in view of its good experimental antitumour activity (Stevens et al., 1987) and much lower toxicity in the pre-clinical screen. In the pre-clinical toxicology a toxic dose for temozolomide could not be obtained because of the toxicity of the solvent DMSO but was >420mgm-2. In addition, unlike mitozolomide, the antitumour activity of temozolomide was schedule-dependent (Stevens et al., 1987) . The pharmacokinetics of temozolomide were studied in selected patients at each dose level and blood samples collected into heparinised tubes just prior to temozolomide administration and at 0.5, 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 6, 8, 12 and 24 h post dosing.
Sample collection All syringes and tubes for the collection of samples were pre-cooled to 4°C and samples maintained at that temperature. Blood samples were transferred to lithium heparinised tubes and immediately centrifuged at 2,000 r.p.m. for 10 min at 4°C. Known volumes of plasma, whole blood or urine were transferred to sterilin bijoux pots containing 1 N HC1 (0.1 ml ml ' fluid) and stored at -18°C until analysis.
Plasma temozolomide
To 0.1 ml acidified plasma, was added 75 glI internal standard (ethyl analogue of temozolomide) solution. Three ml ethyl acetate was added, vortexed for 2 x 10 s, and centrifuged at 3,000 r.p.m. for 10 min. Two ml organic layer was transferred to sample concentrator tubes and evaporated to dryness at 45°C. A further 3 ml ethyl acetate was added to the remaining aqueous phase which was then vortexed and centrifuged. Three ml organic layer was removed and transferred to the sample concentrator tubes containing the dried residue of the first extraction. After evaporation to dryness, the residue was reconstituted in 125 gil methanol and 125 glI 0.5% acetic acid added. Samples were transferred to 0.4 ml microfuge vials and centrifuged in a Beckman microfuge for 5 min. The supernatant was taken for analysis by HPLC Calibration To 0.1 ml acidified plasma, whole blood or urine (0.1 ml 1 N HCI/1.0 ml fluid) known amounts of temozolomide were added in 0.1 N HCI between the range 0.2 and 6 gig ml-'. A volume of 0.1 N HCI was added to make a total of 75 gIl using a solution of 1% DMSO in 0.1 N HCI.
HPLC analysis
The samples were analysed utilising a Waters WISP 710B, 510 pump, 480 UV detector and a 840 data and chromatography control station. The chromatographic conditions were: Column -Lichrosorb RP-Select B (125 x 4 mm), UV -325 nm, mobile phase -10% methanol in 0.5% acetic acid, flow rate -1.8 ml min-', injection volume -0.035 ml. Temozolomide retention time 2.0 min internal standard 4.5 min .
Results
The trial has been conducted in two parts: the first 51 patients were treated with the single dose schedule. Their mean age was 52 years and their diagnoses were melanoma, 14; renal, four; breast, four; colorectal, four; stomach, three; glioma, three; others 15. Doses of temozolomide up to 200 mg m-2 were administered intravenously. Oral bioavailability at this latter dose was studied in five patients who received temozolomide both orally and intravenously on two separate occasions at least 4 weeks apart. Data from each patient are presented in Table I and that of one patient presented in Figure 2 . Having demonstrated good bioavailability at 200mgm-2 subsequent dose escalations up to 1,200 mg m2 were given orally. The pharmacokinetics of temozolomide is linear with dose ( Figure 3 ). Parameters obtained in nine patients dosed intravenously and in 25 patients following oral administration are summarised in Table II. After intravenous administration, plasma temozolomide concentrations declined biexponentially and could be described by a two compartment model with a distribution half life of 1.8 h. After oral dosing however, plasma concentrations in most instances have been fitted to a one compartment model. Temozolomide was rapidly absorbed, with maximum plasma concentrations being attained 0.7 h post dosing. Over the concentration range studied, temozolomide pharmacokinetics were not dose dependent and the relationship between dose and the area under the plasma concentration vs time curve was linear (r = 0.858), see Figure 3 . Clearance of temozolomide was estimated to be 11.8 1 h-'. Plasma temozolomide concentrations in some patients displayed a secondary absorptive phase as late as 4 h post dosing which is likely to reflect entero-hepatic recycling.
The data relating to the two patients receiving oral temozolomide on three separate occasions indicates that INTRA-subject variability in plasma concentrations is small.
Pharmacokinetics of temozolomide during the 5 day schedule have only been studied in one individual when plasma concentrations were determined on Day 1 and Day 5. There was no accumulation of temozolomide -the area under the plasma concentration vs time curve being 34.8 and 23.1 mg I h-' on Days 1 and 5 respectively.
The symptomatic toxicity from temozolomide on the single dose schedule was mainly nausea and vomiting. This was usually mild to moderate (WHO 1-3) at doses up to 700 mg m-2 but at higher doses some patients experienced Grade 4 Bioavailability calculated without consideration of the small differences in apparent elimination half life. Tables III and IV) tumour activity in mice (Stevens et al., 1987) , doses of 750, 900, 1,000 and 1,200mgm-2 were administered as a 5 day schedule in 42 patients on a 4 week cycle (Table V) . Nausea and vomiting on this schedule was usually limited to Day 1 and was readily controlled with antiemetics. In contrast to mitozolomide the 5 day schedule of temozolomide was not more myelosuppressive than the single dose schedule (Schornagel et al., 1986) . In order to avoid occasional Grade 4 haematological toxicity, it is recommended that the initial course should be at a dose of 150 mg m2 po for 5 days (total dose 750 mg m2), on a 4 week cycle. If no major myelosuppression is detected on day 22 of the 4 week cycle, the subsequent courses can be given at a dose of 200 mg m-2 po for 5 days (total dose 1 g m-2) which was in general well tolerated haematologically (Tables VI and VII) . Over a 19 month period nausea and vomiting on the 5 day oral schedule of 750 mg m2 (total dose), was WHO grade 0 in 11 (29%); one in seven (18%); two in nine (24%); three in ten (26%); four in one (3%) in 38 evaluable courses. At 1,000 mg m-2 (total dose), the nausea and vomiting was WHO grade 0 in 25 (49%); one in five (10%); two in 15 (29%); three in six (12%); four in 0 (0%) in 51 evaluable courses. Non haematological toxicity was mild with alopecia WHO grade 1 in one patient, skin rash grade 2 in one patient and renal toxicity grade 1 in one patient. Constipation and headaches occurring in several patients were attributed to concurrent ondansetron. Two courses were not evaluable for toxicity on Tables VI and VII for the following reasons: (i) no laboratory results were taken after last course; (ii) early death following last course. Clinical experience so far shows little cumulative toxicity associated with temozolomide at this dose which is much easier to handle than mitozolomide. Evidence of clinical activity was seen in a number of patients (Table VIII) . The Phase I trial was targeted towards melanoma since at physiological pH, temozolomide spontaneously activates to MTIC the putative active metabolite of dacarbazine, an existing anti-melanoma agent (Figure 1 ). A total of 14 patients with metastatic melanoma were entered on the single dose schedule dose between 50 and 1,000mg m-2 but no responses were seen. Twenty-three patients with melanoma were entered on the 5 day schedule with doses between 750 and 1,200 mg m-2. A complete response lasting 6 months was seen in one patient with recurrent cutaneous metastases and a very good partial response lasting 7 months was seen in a patient with pulmonary and hepatic disease (the patient having a complete response on chest X-ray from multiple pulmonary metastases). Two other patients with melanoma responded for 4 and 5 months respectively producing a response rate of four (17%) out of 23 patients. One patient with drug resistant mycosis fungoides (previous chemotherapy included vincristine, chlorambucil, prednisolone, bleomycin, etoposide, methotrexate, cyclophosphamide, adriamycin and mitozantrone), had a dramatic response lasting 7 months and has currently achieved a second complete remission after restarting temozolomide. In addition, activity has been seen in recurrent high grade gliomas. Clinical improvement was seen in two patients with glioma during the dose escalation part of the study. Temozolomide is known to cross the blood brain barrier in mice (P. Antoniw, E.S. Newlands, unpublished observations) and therefore further patients with glioma were entered in this trial. To March 1991 good partial responses on CT scan with dramatic clinical improvements have been seen in two patients with recurrent high grade gliomas after prior surgery and radiotherapy (Table XII) .
Discussion
Temozolomide is an analogue of mitozolomide but, unlike the latter drug, can be readily administered orally on a 5 day schedule. The new drug usually elicits predictable and reversible myelosuppression. Doses up to 1 g m2 (given in equal doses over 5 days) can be administered with acceptable haematological toxicity and with little evidence of cumulative toxicity. Clinical activity has been seen in malignant melanoma, mycosis fungoides and high grade gliomas. The recommended dose for further studies is 750mgm-2 split over 5 days and if no myelosuppression is detected on day 22 blood counts subsequent courses can be given at 1 g m-2 split over 5 days given orally and repeated on a 4 week cycle. Distribution studies performed in mice confirmed that temozolomide like mitozolomide (Brindley et al., 1986 and unpublished observations) , has good tissue distribution including penetration into tumour tissue and the central nervous system. This extended Phase I study indicates that temozolomide warrants further evaluation in Phase II studies in melanoma, gliomas and lymphoma and other tumour types. 
